Cambodia

Population 2017: 16 million

Estimated TB burden*, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>3.1 (2.4–4.3)</td>
<td>19 (13–27)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.41 (0.27–0.57)</td>
<td>2.6 (1.7–3.6)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>52 (36–72)</td>
<td>328 (224–447)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.3 (0.89–1.8)</td>
<td>8.2 (5.6–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>1.2 (0.52–2.1)</td>
<td>7.2 (3.2–13)</td>
</tr>
</tbody>
</table>

Mortality (excludes HIV+TB) 3.1 (2–4.3)

Incidence (HIV+TB only) 0.41 (0.27–0.57)

Incidence (HIV+TB only) 1.3 (0.89–1.8)

Incidence (MDR/RR-TB)** 1.2 (0.52–2.1)

Incidence rate (per 100,000 population per year)

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017: 66% (48–96)

TB patients facing catastrophic total costs: 0.07 (0.04–0.1)

TB/HIV care in new and relapse TB patients, 2017

Patients with known HIV-status who are HIV-positive: 748, 3%

- on antiretroviral therapy: 698, 93%

Drug-resistant TB care, 2017

Estimated MDR/RR-TB cases among notified pulmonary TB cases: 560 (290–840)

Estimated % of TB cases with MDR/RR-TB: 1.8% (0.9–3)

% notified tested for rifampicin resistance: 33%, 1,313

MDR/RR-TB cases tested for resistance to second-line drugs: 100

Laboratory-confirmed cases

Patients started on treatment ****

MDR/RR-TB: 136, XDR-TB: 1

MDR/RR-TB: 143, XDR-TB: 1

Treatment success rate and cohort size

New and relapse cases registered in 2016: 94%, 32,478

Previously treated cases, excluding relapse, registered in 2016: 92%, 36

HIV-positive TB cases registered in 2016: 71%, 75

MDR/RR-TB cases started on second-line treatment in 2015: 71%, 75

XDR-TB cases started on second-line treatment in 2015: 0

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment: 21%

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 44% (40–48)

TB financing, 2018

National TB budget (US$ millions): 37

Funding source: 12% domestic, 24% international, 64% unfunded

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-06-10

Data: www.who.int/tb/data